Matches in SemOpenAlex for { <https://semopenalex.org/work/W2125624222> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2125624222 endingPage "266" @default.
- W2125624222 startingPage "245" @default.
- W2125624222 abstract "Cells at the maternal-fetal interface express indoleamine 2,3 dioxygenase (IDO) to consume all local tryptophan for the express purpose of starving adjacent maternal T cells of this most limiting and essential amino acid. This stops local T cell proliferation to ultimately result in the most dramatic example of immune tolerance, acceptance of the fetus. By contrast, inhibition of IDO using 1- methyl-tryptophan causes a sudden catastrophic rejection of the mammalian fetus. Immunomodulatory factors including IFNγ , TNFα , IL- 1, and LPS use IDO induction in responsive antigen presenting cells (APCs) also to transmit tolerogenic signals to T cells. Thus it makes sense to consider IDO induction towards tolerance for autoimmune diseases in general. Approaches to cell specific therapeutic IDO induction with NAD precursor supplementation to prevent the collateral non-T cell pathogenesis due to chronic TNFα -IDO activated tryptophan depletion in autoimmune diseases are reviewed. Tryptophan is an essential amino acid most immediately because it is the only precursor for the endogenous biosynthesis of nicotinamide adenine dinucleotide (NAD). Both autoimmune disease and the NAD deficiency disease pellagra occur in women at greater than twice the frequency of occurrence in men. The importance of IDO dysregulation manifest as autoimmune pellagric dementia is genetically illustrated for Nasu-Hakola Disease (or PLOSL), which is caused by a mutation in the IDO antagonizing genes TYROBP/DAP12 or TREM2. Loss of function leads to psychotic symptoms rapidly progressing to presenile dementia likely due to unchecked increases in microglial IDO expression, which depletes neurons of tryptophan causing neurodegeneration. Administration of NAD precursors rescued entire mental hospitals of dementia patients literally overnight in the 1930s and NAD precursors should help Nasu-Hakola patients as well. NAD depletion mediated by peroxynitrate PARP1 activation is one of the few established mechanisms of necrosis. Chronic elevation of TNFα leading to necrotic events by NAD depletion in autoimmune disease likely occurs via combination of persistent IDO activation and iNOS-peroxynitrate activation of PARP1 both of which deplete NAD. Pharmacological doses of NAD precursors repeatedly provide dramatic therapeutic benefit for rheumatoid arthritis, type 1 diabetes, multiple sclerosis, colitis, other autoimmune diseases, and schizophrenia in either the clinic or animal models. Collectively these observations support the idea that autoimmune disease may in part be considered as localized pellagra manifesting symptoms particular to the inflamed target tissues. Thus pharmacological doses of NAD precursors (nicotinic acid/niacin, nicotinamide/niacinamide, or nicotinamide riboside) should be considered as potentially essential to the therapeutic success of any IDO-inducing regimen for treating autoimmune diseases. Distinct among the NAD precursors, nicotinic acid specifically activates the g-protein coupled receptor (GPCR) GPR109a to produce the IDO-inducing tolerogenic prostaglandins PGE2 and PGD2. Next, PGD2 is converted to the anti-inflammatory prostaglandin, 15d-PGJ2. These prostaglandins exert potent anti-inflammatory activities through endogenous signaling mechanisms involving the GPCRs EP2, EP4, and DP1 along with PPAR respectively. Nicotinamide prevents type 1 diabetes and ameliorates multiple sclerosis in animal models, while nothing is known about the therapeutic potential of nicotinamide riboside. Alternatively the direct targeting of the non-redox NAD-dependent proteins using resveratrol to activate SIRT1 or PJ34 in order to inhibit PARP1 and prevent autoimmune pathogenesis are also given consideration. 1. Keywords: NAD, autoimmune disease, pellagra, IDO, tryptophan, niacin, rheumatoid arthritis, type 1 diabetes" @default.
- W2125624222 created "2016-06-24" @default.
- W2125624222 creator A5065857191 @default.
- W2125624222 date "2007-04-01" @default.
- W2125624222 modified "2023-10-10" @default.
- W2125624222 title "Pharmacological Targeting of IDO-Mediated Tolerance for Treating Autoimmune Disease" @default.
- W2125624222 cites W1967958074 @default.
- W2125624222 cites W2417669554 @default.
- W2125624222 doi "https://doi.org/10.2174/138920007780362545" @default.
- W2125624222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17430113" @default.
- W2125624222 hasPublicationYear "2007" @default.
- W2125624222 type Work @default.
- W2125624222 sameAs 2125624222 @default.
- W2125624222 citedByCount "52" @default.
- W2125624222 countsByYear W21256242222012 @default.
- W2125624222 countsByYear W21256242222013 @default.
- W2125624222 countsByYear W21256242222014 @default.
- W2125624222 countsByYear W21256242222015 @default.
- W2125624222 countsByYear W21256242222016 @default.
- W2125624222 countsByYear W21256242222017 @default.
- W2125624222 countsByYear W21256242222018 @default.
- W2125624222 countsByYear W21256242222019 @default.
- W2125624222 countsByYear W21256242222020 @default.
- W2125624222 countsByYear W21256242222021 @default.
- W2125624222 countsByYear W21256242222022 @default.
- W2125624222 countsByYear W21256242222023 @default.
- W2125624222 crossrefType "journal-article" @default.
- W2125624222 hasAuthorship W2125624222A5065857191 @default.
- W2125624222 hasConcept C159654299 @default.
- W2125624222 hasConcept C181199279 @default.
- W2125624222 hasConcept C203014093 @default.
- W2125624222 hasConcept C2776090121 @default.
- W2125624222 hasConcept C2776706248 @default.
- W2125624222 hasConcept C2777702733 @default.
- W2125624222 hasConcept C2779075594 @default.
- W2125624222 hasConcept C515207424 @default.
- W2125624222 hasConcept C54355233 @default.
- W2125624222 hasConcept C55493867 @default.
- W2125624222 hasConcept C71924100 @default.
- W2125624222 hasConcept C75520062 @default.
- W2125624222 hasConcept C83478079 @default.
- W2125624222 hasConcept C86803240 @default.
- W2125624222 hasConcept C8891405 @default.
- W2125624222 hasConceptScore W2125624222C159654299 @default.
- W2125624222 hasConceptScore W2125624222C181199279 @default.
- W2125624222 hasConceptScore W2125624222C203014093 @default.
- W2125624222 hasConceptScore W2125624222C2776090121 @default.
- W2125624222 hasConceptScore W2125624222C2776706248 @default.
- W2125624222 hasConceptScore W2125624222C2777702733 @default.
- W2125624222 hasConceptScore W2125624222C2779075594 @default.
- W2125624222 hasConceptScore W2125624222C515207424 @default.
- W2125624222 hasConceptScore W2125624222C54355233 @default.
- W2125624222 hasConceptScore W2125624222C55493867 @default.
- W2125624222 hasConceptScore W2125624222C71924100 @default.
- W2125624222 hasConceptScore W2125624222C75520062 @default.
- W2125624222 hasConceptScore W2125624222C83478079 @default.
- W2125624222 hasConceptScore W2125624222C86803240 @default.
- W2125624222 hasConceptScore W2125624222C8891405 @default.
- W2125624222 hasIssue "3" @default.
- W2125624222 hasLocation W21256242221 @default.
- W2125624222 hasLocation W21256242222 @default.
- W2125624222 hasOpenAccess W2125624222 @default.
- W2125624222 hasPrimaryLocation W21256242221 @default.
- W2125624222 hasRelatedWork W2006819290 @default.
- W2125624222 hasRelatedWork W2023470890 @default.
- W2125624222 hasRelatedWork W2057871663 @default.
- W2125624222 hasRelatedWork W2066388260 @default.
- W2125624222 hasRelatedWork W2088605151 @default.
- W2125624222 hasRelatedWork W2356110158 @default.
- W2125624222 hasRelatedWork W2782960396 @default.
- W2125624222 hasRelatedWork W3004607099 @default.
- W2125624222 hasRelatedWork W3028948306 @default.
- W2125624222 hasRelatedWork W3032347053 @default.
- W2125624222 hasVolume "8" @default.
- W2125624222 isParatext "false" @default.
- W2125624222 isRetracted "false" @default.
- W2125624222 magId "2125624222" @default.
- W2125624222 workType "article" @default.